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Objective To determine whether the age-specific refer- 
ence ranges for serum prostate-specific antigen (PSA) 
concentration generated for white men are applicable 
to other races. 
Patients and methods Three-hundred and thirty-five 
healthy Japanese men, aged 40-79 years, residing in 
the small fishing village of Shimamaki-mura, Japan, 
agreed to enter this prospective, community-based 
study. All underwent a detailed clinical evaluation 
that included a serum PSA determination, a digital 
rectal examination and a transrectal ultrasound. Two- 
hundred and eighty-six (8 5%) completed the prostatic 
evaluation and had no evidence of prostate cancer by 
any one of the three diagnostic tests; these men formed 
the study population on which all analyses were 
performed. 
Results The serum PSA concentration correlated directly 
with patient age ( r=0 .33;  P<O.OOl)  and prostatic 
volume (r=0.57; P<O.OOl) .  PSA density (PSAD) also 
was directly proportional to age (r = 0.30: P < 0.001). 
Adjusting for age, the serum PSA concentration 
was lower for Japanese men than for white men 
( P  <0.001). Thus, the recommended age-specific 
reference ranges (95th percentile) for serum PSA for 
Japanese were lower as well: 0.0-2.0ng/mL for 
40-49 years; 0.0-3.0 ng/mL for 50-59 years; 
0.0-4.0 ng/mL for 60-69 years: and 0.0-5.0 ng/mL 
for 70-79 years. Based on transrectal ultrasound- 
volume- determinations, the lower serum PSA concen- 
trations in Japanese men are due in large part to their 
smaller prostate glands as compared with white men 
( P  < 0.001). 
Conclusions These findings confirm the earlier obser- 
vations that serum PSA, prostatic volume and PSAD 
are age-dependent. However, because of physiological 
differences among the two races, partly due to the sue 
of the prostate gland, the age-specific reference ranges 
for serum PSA are lower for Japanese men than for 
white men. Because of these racial differences, it is 
now crucial to conduct a similar investigation among 
black men. 
ICeywords Prostate-specific antigen, age-specific refer- 
ence ranges, Japanese, white men, race 
Introduction 
Prostate-specific antigen (PSA) is the most clinically 
useful tumour marker available today for the diagnosis 
and management of prostate cancer [l]. Nevertheless, 
because it is produced by all types of prostatic tissue - 
normal, benign hyperplastic and cancerous - it lacks 
sufficient sensitivity and specificity to be the ‘perfect’ 
tumour marker for the detection of early prostate cancer. 
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To further improve PSA as a screening test for prostate 
cancer, numerous investigators have developed and 
explored various concepts. These include: (i) PSA density 
(PSAD), which is the quotient of the serum PSA concen- 
tration divided by the volume of the prostate gland [2 ,3] ;  
(ii) PSA velocity (PSAV), which is the longitudinal 
change in serum PSA level over time [4,5]: (iii) free 
versus complexed serum PSA, which refers to the ratio 
of free PSA to PSA complexed to alpha,-antichymo- 
trypsin (ACT) in the serum [6,7]: and (iv) age-specific 
reference ranges as opposed to the single reference range 
of 0.0-4.0 ng/mL for men of all ages [8,9]. 
In a recent investigation, Oesterling et ul. examined 
the distribution of serum PSA values in a population of 
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men with no evidence of prostate cancer but who were 
at risk of developing the condition [8]. Five-hundred and 
thirty-seven healthy men were chosen randomly from 
Olmsted County, Minnesota, USA to participate: all were 
white and between 40 and 79 years of age, and under- 
went a detailed clinical evaluation that included a serum 
PSA determination, a meticulous digital rectal examin- 
ation (DRE) and a transrectal ultrasound (TRUS). Four- 
hundred and seventy-one men (88Yo) completed the 
protocol and had no evidence of prostate cancer by any 
of these diagnostic tests. Based on data from this popu- 
lation, the serum PSA concentration correlates directly 
with age (r=0.43; P<O.OOl) .  For a healthy 60-year- 
old man with no evidence of prostate cancer, the serum 
PSA concentration increases by approximately 3.2% per 
year (0.04 ng/mL/y; Tandem-R or IMx PSA assay). 
Because of this relationship between PSA and age, the 
upper limit of normal for serum PSA increases with 
advancing age. Using the 9 5th percentile, these investi- 
gators determined the upper limit of normal to be 
2.5 ng/mL for men aged 40-49 years, 3.5 ng/mL for 
men aged 50-59 years, 4.5 ng/mL for men 60-69 years 
and 6.5 ng/mL for men 70-79 years. 
These results as well as those from other independent 
investigations [9,10] confirming the correlation between 
serum PSA and patient age, however, were obtained from 
white men. No data are available for either black or Asian 
men. In this report the serum PSA findings from a 
community-based study involving men from a Japanese 
fishing village are presented, and age-specific reference 
ranges for serum PSA in Japanese men are given. 
Methods 
Patient populution 
Between December 1990 and March 1992, all men aged 
40-79 years residing in Shimamaki-mura, a small fish- 
ing village in northern Japan, with no history of prostate 
cancer, prostatectomy or other specified conditions that 
interfere with voiding function were invited to participate 
in a prospective study to assess the natural history of 
benign prostate hyperplasia (BPH). The study design and 
participant selection process were very similar to those 
for the community-based population study performed in 
Olmsted County, Minnesota, USA [ll]. Of the 682 men 
invited, 335 (49%) agreed to participate. All underwent 
a detailed clinical evaluation that included a serum PSA 
determination, a DRE and a TRUS. Forty-five men (1 3%) 
either met exclusion criteria or did not complete all three 
diagnostic tests, and were excluded from further analysis. 
Thirty-six (1 1%) underwent a TRUS-guided biopsy of the 
prostate, four of whom (1 1%) were found to have cancer. 
These latter men also were excluded from participation. 
Thus, 286 men (85%) completed the protocol and 
had no evidence of prostate cancer by any of the three 
diagnostic tests: these men formed the study population 
on which all analyses were performed. The mean 
agefstandard deviation was 61 f10 .3  years: 47 (16%) 
were between 40 and 49, 64 (22%) between 50 and 
59, 106 (37%) between 60 and 69, and 69 (24%) 
between 70 and 79 years of age. 
Techniques 
All serum PSA concentrations were determined with the 
same IMx PSA assay (Abbott Laboratories; Abbott Park, 
Illinois, USA). The standard reference range for this 
assay is 0.0-4.0 ng/mL [12]. All PSA determinations 
were made prior to any prostatic manipulations, includ- 
ing DRE and TRUS. The DRE was performed with the 
patient in the knee-chest position. 
The TRUS was performed similarly for all men using 
a 7.5 MHz, biplanar endorectal transducer. In addition 
to assessing the echogenic pattern of the prostate gland, 
three measurements were made to calculate the prostatic 
volume. The anterior-posterior (AP) and transverse (TR) 
diameters were measured at their respective maximal 
dimensions, whereas the superior-inferior (SI) diameter 
was measured at the maximal length from the base to 
the apex of the prostate in the midline sagittal plane. 
The prostatic volume was calculated from the formula 
of a prolate ellipsoid, Volume=0.52 (TR x AP x SI) [13]. 
For this investigation, PSAD was calculated by dividing 
the serum PSA concentration by the prostatic volume, 
as determined from TRUS. 
Any patient with an elevated serum PSA concen- 
tration, abnormal DRE result or suspicious lesion on 
TRUS was evaluated for a prostatic malignancy. If the 
DRE and TRUS were unremarkable but the serum PSA 
level was elevated ( > 4.0 ng/mL), a sextant biopsy (three 
cores from each side) of the prostate was performed. An 
abnormal DRE or TRUS result, irrespective of serum PSA 
level, prompted a biopsy of the area in question; in 
addition, a sextant biopsy of the remaining prostate was 
performed. 
Statistical analysis 
Descriptive statistics were calculated for the entire study 
cohort and for 10-year age groups for the clinical 
parameters, PSA level, prostatic volume and PSAD. 
Because of the log-normal distribution, PSA levels, pros- 
tatic volumes and PSAD values were log-transformed 
for analysis. Pearson product-moment correlation 
coefficients were calculated to measure the association 
between serum PSA and age, prostatic volume and 
age, PSA and prostatic volume, and PSAD and age. 
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Least-squares regression models were constructed using 
the transformed data to evaluate the association between 
prostatic volume and age jointly with serum PSA levels. 
Using the regression models, the 95th percentile was 
determined as the upper limit of normal (reference range) 
for the midpoint of each 10-year age group for the serum 
PSA concentration and PSAD [14]. For prostatic volume, 
the 97.5th percentile was used as the upper limit of 
normal and the 2.5th percentile as the lower limit of 
normal for the midpoint of each 10-year age group. For 
all analyses, a P-value < 0.05 was considered statistically 
significant. 
Nomograms portraying the distribution of serum PSA 
levels, prostatic volumes and PSAD values as a function 
of age were generated based on the least-squares 
regression models. A nomogram depicting the distri- 
bution of serum PSA levels as a function of prostatic 
volume also was constructed in a similar manner. 
Results 
With regard to the outcome variables, the median (25th, 
75th percentiles) serum PSA concentration for the entire 
study group was 0.8 (0.5, 1.5) ng/mL, the median 
prostatic volume was 18 (15, 21) mL and the median 
PSAD was 0.05 (0.03, 0.08) ng/mL/mL. 
Serum PSA and age 
In general, the median serum PSA value increased with 
each decade of age (Table 1). Between 40 and 49 years 
of age, no individual had a serum PSA level > 4.0 ng/mL, 
between 50 and 59 years, one (2%), between 60 and 
69 years, three (3%), and between 70 and 79 years, five 
(7%) individuals had a serum PSA concentration above 
the standard reference range (0.0-4.0 ng/mL) and no 
clinical evidence of prostate cancer. Overall, nine men 
(3%) had a serum PSA level >4.0 ng/mL. 
The serum PSA concentration as a function of age for 
Fig. 1. Serum prostate-specific antigen 
(PSA) concentration as a function of patient 
age. Scattergram of the individual serum 
PSA values for all 286 men, with a 
nomogram demonstrating the 2.5th, Sth, 
25th. Wth, 75th, 95th. and 97.5th 
percentiles for serum PSA according to age. 
Table 1 Serum PSA concentration, prostatic volume and PSA 
density as a function of age 
Age range Serum PSA Proslatic volume PSA density 

























* Median value. t 25th and 75th percentiles, respectively 
all 286 men is presented in Fig. 1. Over the entire age 
range, the serum PSA concentration correlated directly 
with age (r=0.33; P<O.OOl) .  Based on the regression 
analysis of these cross-sectional data, the serum PSA 
concentration would increase by approximately 2.6% 
per year. For a 60-year-old man, this would correspond 
to an increase of 0.02 ng/mL over the following year. 
The nomogram for serum PSA with regard to patient 
age also is shown in Fig. 1. Based on these data, the 
appropriate upper limit of normal (9 5th percentile) for 
the serum PSA concentration increases with age, from 
2.0ng/mL for a 45-year-old man to 5.0ng/mL for a 
75-year-old man. The estimated reference range for each 
10-year age group is given in Table 2. 
Prostatic volume and age 
Like PSA, the median prostatic volume increased with 
each decade of life (Table 1). No man between 40 and 
59 years of age had a prostate gland that was > 50 mL 
in size. Between 60 and 79 years, four men (2%) had a 
prostate > 50 mL for two of these, the prostate was 
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Table 2 Age-specific reference ranges* for serum PSA concen- 
tration, prostatic volume and PSA density 
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Fig. 2. Prostatic volume as a function of 
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Age range Serum PSA Prostatic volume PSA density 
hears)  (nglmL) W )  (nglmLlmL) 
40-49 0.0-2.0 9-33 0.0-0.10 
50-59 0.0-3.0 9-35 0.0-0.12 
60-69 0.0-4.0 10-37 0.0-0.1 5 
70-79 0.0-5.0 11-40 0.0-0.18 
* For serum PSA concentration and PSA density the upper limit of 
normal was defined as the 95th percentile for the midpoint of age 
range from regression analysis; for prostatic volume the 97.5th 
percentile was used to define the upper limit. The lower limit was 
set at 0.0 for PSA concentration and PSA density and t .5th 
percentile for prostatic volume 
The prostatic volume for each study participant is 
plotted by age in Fig. 2. For the entire age group the 
prostatic volume correlated directly with age (r= 0.19: 
P < 0.01). The regression analysis suggests that the 
prostatic volume would increase by approximately 
O.b%/year. For a 60-year-old man this would correspond 
to an increase of 0.11 mL over the ensuing year. The 
nomogram for prostatic volume as a function of age also 
is presented in Fig. 2, and the calculated reference range 
(2.5 th percentile to 9 7.5th percentile) for prostatic 
volume for each 10-year age group is presented in 
Table 2. 
Serum PSA and prostatic volume 
The individual serum PSA value as a function of the 
prostatic volume is plotted in Fig. 3. Over the entire 
range of prostatic sizes, the serum PSA concentration 
correlated directly with prostatic volume (r= 0.5 7; 
P<O.OOl). Based on the regression analysis of these 
cross-sectional data, the serum PSA concentration would 
increase by 5.4% per millilitre of prostatic tissue. For a 
25 mL prostate gland, this would mean an increase of 
0.07 ng1n-L for each millilitre of enlargement in size. 
The nomogram for serum PSA concentration with regard 
to prostatic volume also is given in Fig. 3 .  The results of 
the regression analysis suggest that 3 3% of the variance 
in PSA can be accounted for by prostatic volume, and 
age accounts for an additional 5% (P< 0,001). 
PSAD and age 
While PSA and prostatic volume both increased with 
age, the median PSAD Ievel increased only moderately 
with each decade of life (Table 1). For the study partici- 
pants between the ages of 40 and 49 years, one man 
(2%) had a PSAD>O.15 ng/mL/mL (the previously sug- 
gested upper limit for PSAD to distinguish early prostate 
cancer from BPH (15); between 50 and 59 years, 1 
(2%); between 60 and 69 years, 5 (5%); and between 
70 and 79 years, 6 (9%) had a PSAD above this cutpoint. 
For the entire study population, 13  men (5%) had a 
PSAD value > 0.15 ng/mL/mL. 
Each study participant's individual PSAD value as a 
function of age is presented in Fig. 4. For the entire 
age group, PSAD is correlated directly with age, as is 
suggested by the r-value of 0.29 (P<O.OOl). Based on 
the regression analysis, the PSAD would increase by 
1.9%/year. For a 60-year-old man, this would corre- 
spond to an increase of 0.001 ng/mL/mL over one 
year's time. The homogram for PSAD with regard to 
patient age is provided in Fig. 4, and the appropriate 
upper limit of normal (95th percentile) for PSAD for 
each 10-year age group is given in Table 2. 
Discussion 
This investigation, based on a community population of 
healthy Japanese men with no clinical evidence of 
prostate cancer, is the first study to define 'normal levels' 
for serum PSA level as well as for prostatic volume and 
PSAD among non-whites. All previous studies examining 
these variables involved white populations [%lo]. 
50 1 . I Percentile 
I I nomogram demonstrating the 2.5th, 5th, 
40 50 60 70 80 
Age (Y) 
25th. 50th. 75th. 95th. and 97.5th 
percentiles for prostatic volume according 
to age. 
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Fig. 3. Serum prostate-specific antigen 
(PSA) concentration as a function of 
prostatic volume. Scattergram of the 
individual values for all 286 men, with a 
nomogram demonstrating the 2.5th, Sth, 
25th, 50th, 75th. 95th. and 97.5th 
percentiles for serum PSA according to 
prostatic volume. 
Fig. 4. Prostate-specific antigen density 
(PSAD) as a function of patient age. 
Scattergram of the individual PSAD values 
for all 286 men, with a nomogram 
demonstrating the 2.5th. 5th, 25th, 50th. 
75th. 95th. and 97.5th percentiles for 






























Thus, this investigation affords a valuable opportunity 
not only to describe the appropriate reference ranges for 
Japanese men but also to determine if there are racial 
differences. 
In the current study, the serum PSA concentration 
was found to correlate directly with patient age ( r =  
0.33) and with prostatic volume (r=0.57). PSAD and, 
to a lesser degree, prostatic volume also correlated 
directly with patient age (r=0.29 and 0.19, respect- 
ively). These findings are in agreement with the results 
of previous investigations. Oesterling et al., examining 
471 healthy men from Olmsted County, Minnesota, USA, 
found the correlation coefficient between serum PSA and 
age, prostatic volume and age, and PSAD and age to be 
0.43, 0.43, and 0.25, respectively [8]. Collins et al. 
examined these relationships in 472 men with benign 
prostates from central Scotland [ 101. The correlation 
coefficient for serum PSA and patient age in this com- 
munity-based population was 0.3 7, and for prostatic 
volume and age, it was 0.44. Most recently, Dalkin et al. 
examined the relationship between serum PSA and age 
in 728 men older than 50 years of age who had no 
clinical evidence of prostate cancer [9]. They also found 
the serum PSA level to increase with advancing age at a 
statistically significant rate (P < 0.001). Taken together, 
50 60 70 80 
Age (Y) 
these large-scale studies clearly indicate that both the 
serum PSA concentration and prostatic volume are 
dependent upon the patient's age. 
Because of these age-dependent relationships, 
Oesterling et al. as well as Dalkin et al. developed, for 
white men, age-specific reference ranges for serum PSA 
(Table 3 ) .  These reference ranges are somewhat higher 
than those derived for the Japanese men (Table 2). Across 
all age ranges, from 40 to 79 years of age, the upper 
limit of normal for serum PSA for Japanese men is lower 
Table 3 Age-specific reference ranges* for serum as determined 
from two investigations involving white men 
Age range (years) Age-specific reference ranges (nglmL) 









* The upper limit of normal was defined as the 95th percentile for 
the midpoint of each age range using regression analysis. The 
lower limit was set at 0.0 
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than for white men. This implies that a given serum 
PSA value for a Japanese man has a different clinical 
meaning than the same value for a same-aged white 
man. Thus, a serum PSA concentration of 4.2 ng1n-L 
would be considered elevated for a 62-year-old Japanese, 
whereas it would be normal for the same-aged white 
man. Nevertheless, as occurs for the white race, age- 
specific reference ranges make serum PSA a more sensi- 
tive tumour marker for younger Japanese men ( < 70 
years of age) and a more specific tumour maker for older 
Japanese ( > 7 0  years of age). This is exactly what is 
desired for any tumour marker. Although the Japanese 
PSA values were determined by the IMx PSA assay, the 
derived age-specific references ranges are applicable to 
the Tandem-R PSA assay (Hybritech, Inc.. San Diego, 
California, USA) [ 161. 
Establishing PSA reference ranges that are race- 
specific as well as age-specific is intended to produce 
reference ranges with similar levels of specificity in 
different racial groups. However, the positive predictive 
value of these PSA reference ranges will still be higher 
in white men than in Japanese men, because the preva- 
lence of clinically significant prostate cancer is much 
higher amongst the former. Thus, a serum PSA value 
that is elevated above the appropriate race-specific, age- 
specific serum PSA reference range is more likely to 
represent prostate cancer in a white man than in a 
Japanese man. Further experience with clinical use of 
these age reference ranges is needed to quantify the 
extent of these differences. 
The most likely explanation for this difference in the 
age-specific reference ranges for PSA relates to the size 
of the prostate gland for the two races. Across all age 
ranges, the prostates of white men are larger than those 
of Japanese (Table 4) [lo]. Berry et a]., when examining 
the results of several autopsy series from western societ- 
ies, also noted that white men have large prostates [17]. 
The findings of that retrospective, autopsy review are in 
Table 4 Age-specific reference ranges* for prostatic volume and 
PSA density [8] in white men 
Age range Prostatic volume PSA density 









* For PSA density. the upper limit of normal was defined as the 
95th percentile for the midpoint of age range from regression 
analysis; for prostatic volume, the 97.5th percentile was used to 
define the upper limit. The lower limit was set at 0.0 for PSA 
density and 2.5th percentile for prostatic volume 
total agreement with the results that Oesterling et af. 
obtained from TRUS measurements of the Olmsted 
County men. Without question, the bigger the prostate, 
the more epithelial cells that produce and secrete PSA. 
Larger prostates, in general, also tend to have a greater 
degree of obstruction of the prostatic ducts and acini 
due to BPH tissue. In addition, larger prostates often 
contain some inflammation not routinely present in 
smaller, less congested prostates. Even mild, subclinical 
degrees of inflammation can cause a breakdown of the 
normal physiological barriers (basal cells lining the acini, 
basement membrane of the acini, the prostatic stroma, 
capillary endothelial basement membrane and the capil- 
lary endothelial cells) that routinely keep PSA in the 
prostatic ductal system [18]. Because of these phen- 
omena, more PSA will diffuse into the stroma of the 
larger prostate, where it can enter the general circulation 
via the lymphatics and capillaries. However, prostatic 
size alone does not account for all of the difference in 
serum PSA levels between Japanese and white men. The 
difference in serum PSA concentrations between these 
two races remains statistically significant ( P  < 0.001). 
even after adjusting for both prostatic size and patient 
age. 
The elevations of serum PSA levels beyond that which 
can be accounted for by prostatic size alone may reflect 
differences between Japanese and white men and the 
problems of clinically, non-detectable prostate cancer. 
While the autopsy prevalence of previously unsuspected 
(‘latent’) prostate cancer shows little racial or geographic 
variation, the autopsy prevalence of ‘proliferative’ (more 
extensive and less well differentiated) latent prostate 
cancer does show racial and geographic variation similar 
to that seen with clinically diagnosed prostate cancer 
[ 19,201, 
With regard to PSAD, the values obtained for the 
Japanese cohort are greater than those observed for the 
white cohort (Table4). This is due to the fact that the 
prostate glands of Japanese men are significantly smaller 
for the corresponding serum PSA values as compared 
with white men. As a result, the age-specific reference 
ranges for PSAD are higher for Japanese men, while the 
age-specific reference ranges for serum PSA are lower. 
When compared with the standard reference range for 
PSAD (0.0-0.15 ng/mL) [15], these age-specific refer- 
ence ranges for Japanese make PSAD a more sensitive 
parameter in men < 60 years of age and a more specific 
parameter in men > 60 years of age. 
In summary, this investigation of Japanese men con- 
firms the earlier observation that serum PSA. prostatic 
volume and PSAD are age-dependent. Because of this 
phenomenon, it is appropriate to have age-specific 
reference ranges for these parameters in Asian men, as 
has been recommended recently for white men. However, 
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because of physiological differences between the two 
races, particularly with regard to the size of the prostate 
gland, the age-specific reference ranges for serum PSA 
are lower and the age-specific reference ranges or PSAD 
are higher for Japanese than for white men. Thus, with 
regard to serum PSA, prostatic volume and PSAD values, 
there are racial differences - a most important finding. 
It is now crucial to conduct a similar investigation in 
black men, especially since prostate cancer is more 
prevalent, develops at an earlier age, and has a higher 
death rate in this race [21]. By knowing the proper 
reference ranges for these parameters in black men, a 
more accurate and meaningful interpretation of values 
obtained for serum PSA, prostatic volume and PSAD can 
be made on an individual basis. Hopefully, this will 
advance our cause toward earlier detection of prostate 
cancer among black men. 
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